Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia-Reference-Cited by-同舟云学术

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

Published:2017-12 Issue:12 Volume:21 Page:3548-3558
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

An Ding,Schneller Jessica L.,Frassetto Andrea,Liang Shi,Zhu Xuling,Park Ji-Sun,Theisen Matt,Hong Sue-Jean,Zhou Jenny,Rajendran Raj,Levy Becca,Howell Rebecca,Besin Gilles,Presnyak Vladimir,Sabnis Staci,Murphy-Benenato Kerry E.,Kumarasinghe E. Sathyajith,Salerno Timothy,Mihai Cosmin,Lukacs Christine M.,Chandler Randy J.,Guey Lin T.,Venditti Charles P.,Martini Paolo G.V.

Funder

National Human Genome Research Institute

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference55 articles.

1. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics;Akinc;Nat. Biotechnol.,2008

2. Newborn screening expands: recommendations for pediatricians and medical homes--implications for the system;Pediatrics,2008

3. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles;Baba;J. Control. Release,2015

4. Safety profile of RNAi nanomedicines;Barros;Adv. Drug Deliv. Rev.,2012

5. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia;Baumgartner;Orphanet J. Rare Dis.,2014

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Further therapeutic applications of mRNA and saRNA;mRNA Therapeutics;2025

2. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy;Molecular Genetics and Metabolism;2024-09

3. The therapeutic landscape of citrin deficiency;Journal of Inherited Metabolic Disease;2024-07-17

4. Lipid Nanoparticle-Mediated Delivery of mRNA Into the Mouse and Human Retina and Other Ocular Tissues;Translational Vision Science & Technology;2024-07-09

5. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders;ACTA PHARM SIN B;2024